VAERS 2679145
SANOFI PASTEUR · HIB (ACTHIB) · Charge UJ794AA
- Staat
- OH
- Alter
- 0,8
- Geschlecht
- M
- Eingang
- 05.09.2023
- Impfdatum
- 08.06.2023
- Beginn
- 08.06.2023
- Tage bis Beginn
- 0,0
- Dosis
- 4
- Route/Site
- OT / -
Symptomtext
patient was supposed to receive a dose of plain acthib (prp-t), but consumer got hib conjugated with dtap and a separate dtap as well with no reported adverse event; patient was supposed to receive a dose of plain acthib (prp-t), but consumer got hib conjugated with dtap and a separate dtap as well with no reported adverse event; Initial information received on 28-Aug-2023 regarding an unsolicited valid non-serious case received from a other health professional. This case involves a 1 years old male patient who was supposed to receive a dose of plain HIB (PRP/T) vaccine [ACT-HIB] but consumer got hib conjugated with dtap and a separate dtap as well with no reported adverse event. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. Concomitant medications included diphtheria vaccine toxoid, pertussis vaccine acellular, tetanus vaccine toxoid (DTAP) for Prophylactic vaccination (immunization). On 08-Jun-2023, the patient received a dose 4 dose 0.5mL but consumer got it twice making it 1 mL of suspect HIB (PRP/T) Vaccine Powder and solvent for solution for injection lot UJ794AA expiry date: 08-Oct-2023 via intramuscular route in the thigh not specified for Immunization. On 08-JUN-2023 the patient was supposed to receive a dose of plain acthib (prp-t), but consumer got hib conjugated with dtap and a separate dtap as well with no reported adverse event (wrong product administered) (extra dose administered) on the same day following the administration of HIB (PRP/T) Vaccine. Action taken was not applicable. At time of reporting, the outcome was Unknown for the events. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Extra dose administered
- Hospital-Tage
- -
- Labordaten
- -
- Aktuelle Erkrankungen
- -
- Vorgeschichte
- -
- Andere Medikamente
- DTAP
- Allergien
- -
- Vorherige Impfungen
- -